Metastatic Medullary Thyroid Ca Responds to Sorafenib

DENVER — The multikinase inhibitor sorafenib achieved objective responses in 19 of 20 patients with advanced metastatic sporadic or hereditary medullary thyroid carcinoma in a National Cancer Institute-sponsored phase II trial.